Linical Co (TSE:2183) Unearned Premiums

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:2183 Linical Co Ltd TSE:2183
40 GF Score
Price 円205.00
GF Value 円299.47
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Linical Co Unearned Premiums?

Unearned Premiums only applies to insurance companies.

TSE:2183
40GF Score
Linical Co Ltd TSE:2183
Unearned Premiums is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Linical Co (TSE:2183) Overvalued in 2026?

Based on GuruFocus' analysis, Linical Co stock appears to be undervalued. The current stock price of 円205.00 is trading 31.5% below its estimated GF Value™ of 円299.47. GuruFocus considers Linical Co to be Possible Value Trap.

Key valuation signals for TSE:2183:

  • Unearned Premiums:
  • GF Value™: 円299.47 vs. price of 円205.00 (31.5% below fair value)
  • GF Score™: 40/100 with 5 warning signs

No single metric tells the full story. See the TSE:2183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Linical Co Business Description

Address 1-6-1 Miyahara, 10th floor, Shin-Osaka Brick Building, Yodogawa-ku, Osaka, JPN, 532-0003
Linical Co., Ltd. is a Japanese contract research organization (CRO) that provides outsourced clinical development services to pharmaceutical, biotechnology, and medical device companies. Its core services cover clinical trial planning and design, site selection and monitoring, data management, biostatistics, pharmacovigilance and safety monitoring, regulatory affairs, and post-marketing surveillance. The company supports trials across multiple therapeutic areas, including oncology, central nervous system, cardiovascular, and infectious disease. While headquartered in Japan, Linical has expanded internationally through subsidiaries and acquisitions, operating in North America, Europe, and the Asia-Pacific region, including South Korea, Taiwan, and China. Revenue is generated primarily through fee-for-service contracts tied to clinical trial projects, with some full-service and functional outsourcing arrangements. Its clients range from large global pharmaceutical manufacturers to smaller biotech firms seeking regional or global trial support.
40GF Score

Get the complete analysis for TSE:2183

Unearned Premiums is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円205.00
Price
円299.47
GF Value